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A B S T R A C T
Human papillomavirus (HPV) can cause a number of anogenital cancers (i.e., cervical, penile, anal, vaginal,
vulvar) and genital warts. A decade ago, the HPV vaccine was approved, and has been shown to be a public
health achievement that can reduce the morbidity and mortality for HPV-associated diseases. Yet, the mistaken
over-identification of HPV as a female-specific disease has resulted in the feminization of HPV and HPV
vaccines. In this critical review, we trace the evolution of the intersection of science, politics, economics and
gender norms during the original HPV vaccine approval, marketing era, and implementation. Given the focus on
cervical cancer screening, women were identified as bearing the burden of HPV infection and its related
illnesses, and the group responsible for prevention. We also describe the consequences of the feminization of
HPV, which has resulted primarily in reduced protection from HPV-related illnesses for males. We propose a
multilevel approach to normalizing HPV vaccines as an important aspect of overall health for both genders. This
process must engage multiple stakeholders, including providers, parents, patients, professional organizations,
public health agencies, policymakers, researchers, and community-based organizations.
1. Introduction
Vaccinations are one of the top public health achievements of the
early twenty-first century, and the HPV vaccine has the potential to
prevent morbidity and mortality from cervical and other HPV-related
cancer and diseases [1]. The initial HPV vaccine was approved a decade
ago for use in the United States, and although it has been justifiably
lauded as a scientific triumph for disease prevention, it also has been a
source of controversy for various reasons since its 2006 approval. The
vaccine's development and implementation trajectory has been speci-
fically focused on females due its initial testing and marketing to
prevent cervical cancer [2], resulting in direct and indirect gender
biases and corresponding inequities for HPV-related diseases.
Consequently, HPV and its associated interventions have become
feminized. Feminization occurs when an issue's social construction
concentrates on females [3]. The term feminization has historical roots
in the context of poverty during the 1970's and later with the HIV
epidemic. In the case of its 1970's association with poverty, complex
social and economic issues such as unequal pay for equal work, and
increasing divorce rates that led to more women heading single-parent
households introduced the new phenomenon of gender-related pov-
erty. Feminization was associated with HIV when African American
women were identified in the early 2000's as having the highest rates of
HIV acquisition in the U.S., a new phenomenon that changed the “face”
of HIV. With both phenomena, the issue was characterized as female-
focused and layered with perceptions of vulnerability, power imbal-
ances, and gender disparities [4–6]. Additionally, a type of reproduc-
tive technology that has also been feminized is contraception.
Specifically, contraception is more costly for women (financially and
physically), and women are the focus of procreative responsibility, thus
bearing the burden of the contraception responsibility [7]. This
feminization of contraception also generates a strong cultural and
social perception of contraception as feminine, thus excluding males
[8].
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Feminization has the potential to negatively impact public aware-
ness and approaches to address social and health issues across multiple
stakeholder levels (e.g., government, organizations) [4–6]. In this
review, we trace the intersection of science, politics, economics, and
gender norms during the original development, approval and market-
ing phase of the HPV vaccine, in which HPV was characterized as solely
impacting women. In doing so, we extend a longstanding tradition of
critical and feminist scholarship that considers how health sciences can
be used in ways to “discipline” and “regulate” women's bodies by
including HPV in such conversations. [9,10] Accordingly, we review
how the interplay of science and sexism has contributed to the
feminization of HPV and fits within an existing cultural narrative of
HPV being a woman's problem. We conclude by evaluating the impact
of feminization of HPV by examining the HPV vaccine's current
utilization and disparities in the United States, skewed economic
discussions for HPV vaccine policy, and insufficient protection for
males.
2. Cervical cancer, HPV and the HPV vaccine
As early as five centuries ago, the relationship between cervical
cancer and sexual transmission was postulated [11–13]. Since the
1970's, scientific inquiries focused on the connection between papillo-
mavirus infection and cervical cancer, which demonstrated the pre-
sence of HPV DNA in cervical cancer and genital warts [14–16]. In
1983 Harald zur Hausen identified HPV-subtype 16 DNA in precursor
cervical cancer tumors and two years later established that HPV DNA
was present in cervical cancer cells [17]. Following this breakthrough,
lab-based and epidemiological studies evolved, which elucidated the
connection between HPV and cervical cancer (see zur Hausen [18] and
International Agency for Research on Cancer [19] for detailed informa-
tion). This science laid the foundation for future HPV prevention
approaches.
By the year 2000, cervical cancer was the second most common
cancer among women worldwide and approximately half of all women
who had cervical cancer died annually [20]. The global burden from
cervical cancer was far greater in developing nations than in developed
nations that had implemented highly effective screening programs,
which resulted in lower rates of cancer deaths [21]. This global burden
propelled the continued focus on HPV's connection to cervical cancer,
and the quest to identify a vaccine. Critical to the development of the
HPV vaccines, virus-like particles technology allowed for the mechan-
ism to mimic HPV capsid proteins, thus producing neutralizing
antibodies without actually including live HPV DNA in the vaccine
[22–24]. Successive clinical trials assessed the safety and efficacy of
vaccines protecting against HPV-types 16 and 18 [25–27], and HPV-
types 6, 11, 16, and 18 [28–30]. Cervical cancer typically develops over
many years, and identifying an early marker that acted as a “surrogate”
endpoint was critical of early vaccine trials. The clinical endpoints of
these trials were either persistent infection with HPV–targeted types or
cervical/genital disease among women [31].
After years of global vaccine research and development, within the
United States the Food and Drug Administration (FDA) reviewed the
primary evidence of a quadrivalent HPV vaccine (4vHPV; meaning that
four types of HPV - 6, 11, 16 and 18 - were targeted) [32]. This
discussion focused on the efficacy of the vaccine among females 16-to-
26 years of age for cervical, vaginal, and vulvar cancers and their
precursors, and whether immunogenicity data supported the extension
to females 9-to-15 years of age. Given that the sole focus on the vaccine
clinical trial data was on females, the resulting FDA approval of the
vaccine was female specific [32]. Table 1 illustrates this complex
timeline for U.S. HPV vaccine approval and recommendations for
2006–2016. In 2006, the Advisory Committee on Immunization
Practices (ACIP) issued their first recommendation for the vaccine
for females 11-to-12, and approval for the vaccine to be administered
in females ages of 9 through the “catch-up” ages of 13-to-26 years [33].
Following the 4vHPV approval, in 2009, a bivalent vaccine (2vHPV;
types 16 and 18) also was approved by the FDA, but for females 10-to-
25 years of age. Subsequent recommendations that same year by ACIP
expanded the FDA indication for routine vaccination of females 11-to-
12 years, with the same 4vHPV approval protocol from ages 9-through-
26 years [34]. The success of these vaccines, particularly 4vHPV, is
demonstrated by a 64% decrease in HPV types 6, 11, 16, and 18
prevalence among 14-to-19 year old females 6 years after the vaccine's
introduction [35].
3. Implications for male HPV vaccination
In addition to identifying HPV as a cause for cervical cancer, other
studies investigated HPV's connection to anogenital cancers, including
penile and anal cancers [36,37]. The examination of the natural history
of HPV in men occurred a decade after similar studies among women
[38]. Consequently, the lag in the epidemiological evidence for HPV in
males hindered corresponding vaccine recommendations for males.
Three years after initial approval of the first HPV vaccine, ACIP issued
a statement in 2009 that males may be vaccinated with 4vHPV to
prevent genital warts – a “permissive” rather than “routine” approval
for use in males [39]. In 2011, with evidence that 4vHPV prevented
anal pre-cancers, ACIP updated the recommendation for males in-
dicating that males 11-to-12 years should be routinely vaccinated,
males 13-to-21 should be routinely vaccinated as a catch-up group, and
males 22-to-26 who are in high-risk populations, such as men who
have sex with men (MSM), should be vaccinated [40]. The extension of
the age recommendation to high-risk subgroups was the result of cost-
effectiveness data indicating that MSM are at higher risk of anal
cancers and genital warts [41], and would receive additional benefit
from vaccination at later age ranges compared to heterosexual males.
The delay in these recommendations for males was attributed to
limited data regarding HPV's role in anal cancer and genital warts,
and concerns about the cost-effectiveness of vaccinating males
[34,39,40].
4. The evolution of the HPV vaccine to the present
Evolving research during the decade since the vaccine was first
approved has resulted in changes both in the vaccine itself, and in the
dosing schedule. However, policy differences between the two federal
agencies (the FDA and ACIP) responsible for the approval of the
vaccine have resulted in confusing recommendations by age, sex, and
vaccine type (Fig. 1). In December 2014, the FDA approved a 9-valent
HPV vaccine (9vHPV) for females 9-to-26 years of age and in males
from 9-to-15 years of age, but with ACIP subsequently issuing
recommendations in March 2015 that mirrored 4vHPV [42,43].
9vHPV protects against nine HPV types [6, 11, 16, 18, 31, 33, 45, 52
and 58], seven of which are oncogenic, and 9vHPV is 97% effective for
preventing cervical, vaginal, and vulvar cancers caused by the identified
HPV types, and 78% effective for preventing anal cancer [42,44].
Approximately one year later in December 2015, the FDA modified
approval for use of 9vHPV for males to ages 16-to-26 years for the
prevention of anal cancer and genital warts [45]. Most recently, in
October 2016 the FDA approved and in December 2016 ACIP
recommended a two-dose option for 9vHPV for males and females
ages 9 through 14 years, Individuals must be vaccinated before age 15,
and follow a 0 and 6–12 month vaccine delivery schedule [46,47].
These inconsistencies across the HPV vaccine approval timeline have
contributed to impediments to achieving greater coverage in vaccina-
tion uptake and reducing the burden of disease (Fig. 1). Furthermore,
the continued gender-based difference in recommended guidelines
serves to imply that HPV disproportionately affects one gender over
another, when in fact both groups are burdened by HPV-related
cancers and genital warts.
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5. Politics and policy of the HPV vaccine in the United States
While a number of other countries utilize school-based approaches
for nationwide vaccine programs [48], the U.S. relies on vaccine
dissemination primarily through healthcare providers [31]. Even with
national ACIP recommendations provided for HPV vaccination, im-
plementation policy varies state-by-state. Previous and current state
efforts have attempted school-entry mandates [49], yet many of these
legislative efforts have been unsuccessful (e.g., Kentucky, New York,
New Mexico, Texas). Initially, the majority of the legislative bills
focused on educating, providing coverage, or requiring the HPV vaccine
for females only; more recent legislative efforts are transitioning to be
more inclusive of males as well [49]. Only the state of Virginia and the
District of Columbia have been successful in passing and implementing
legislation requiring HPV immunization HPV for school-entry [50].
Virginia's law, however, includes very liberal opt-out language (i.e.,
philosophical exemption) that makes enforcement impossible, and for
both Virginia and the District of Columbia, only girls are included in
the legislation, perpetuating the focus on protection of girls [50]. It was
not until 2014 that the legislation in the District of Columbia was
amended to also include males in this vaccine policy [50]. An
alternative strategy for HPV vaccination mandates is through health
departments [51]. In 2015, Rhode Island became the first state to
successfully implement a gender-neutral HPV vaccine school-entry
requirement, which was institutionalized through the state health
department rather than through legislative means [49].
Due to the separation of state and federal lawmaking in the United
States, individual states can determine and implement state-specific
legislation regarding HPV vaccination requirements and mandates.
According to the National Conference of State Legislatures, 42 states
and territories have introduced legislation related to HPV vaccine
requirements, funding, or education. Yet some states are more
successful than others in the passage of these initiatives [49]. While
policy related to the HPV vaccine may be the most critical strategy for
improving uptake of the HPV vaccine, it is clear that state-level and
community-level politics play an essential role in the state and local
legislators. Thus, political will is required to promote HPV vaccine
legislation in all states and territories.
6. The feminization of HPV: consequences for females
From a scientific standpoint, the creation of the HPV vaccine was
straightforward and an almost perfect case-study of the development of
a highly efficacious and safe vaccine. A more critical investigation,
Table 1
Timeline of FDA approvals and ACIP recommendations for the HPV vaccine in the United States.
Year Month Agency Vaccine Recommendation/Approval
2006 June FDA 4vHPV Approved vaccine for use in females 9–26 years of age
June ACIP 4vHPV Recommended routine vaccine for females 11–12 years; catch-up 13–26 years; can be started at age 9
2009 October FDA 2vHPV Approved vaccine for use in females 10–25 years of age
October ACIP 2vHPV Recommended vaccination for females 11–12 years; catch-up 13–26 years; can be started at age 9
October FDA 4vHPV Approved vaccine for use males 9–26 years of age
October ACIP 4vHPV Recommended vaccination may be given to males age 9–26 years – did not recommend routine vaccination
2011 October ACIP 4vHPV Recommended routine vaccination for males 11–12 years; catch-up 13–21 years and catch-up 22–26 years for men who have sex with
men (MSM) or are immunocompromised; can be started at age 9
2014 December FDA 9vHPV Approved use in females 9–26 years of age
9vHPV Approved use in males 9–15 years of age
2015 February ACIP 9vHPV Recommended routine vaccination for females 11–12 years; catch-up 13–26 years; can be started at age 9
9vHPV Recommended routine vaccination for males 11–12 years; catch-up 13–21 years and catch-up 22–26 years for MSM and men who are
immunocompromised; can be started at age 9
December FDA 9vHPV Approved use in males 16–26 years of age
2016 October FDA 9vHPV Approved use of a two-dose option for males and females 9–14 years
December ACIP 9vHPV Recommended two-dose option for males and females 9–14 years
Fig. 1. Current U.S. approvals and recommendations for HPV vaccination by sex, age, and vaccine type.
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however, reveals how the vaccine developed in tandem with pervasive
gender biases. HPV vaccine research logically proceeded in women
because of the known cytological site of cervical infection and an easily
identified “surrogate” endpoint. There was not an identified cancer in
males that had the prevalence – or the clinical endpoints – that rivaled
cervical cancer, and although genital warts affect males and females, no
males were involved in the initial vaccine trials and the primary
impetus for vaccine development was cancer prevention. The initial
vaccine was approved for adolescent females [33], based upon the
available data and the societal context in which the vaccine was
discovered.
Although typically characterized as a woman's disease, HPV is
sexually transmitted (skin to skin, genital to skin, and oral to genital),
implying contact with another person [52]. It is estimated that nearly
85% of women and 91% of men with at least one sexual partner from
the opposite sex will contract HPV infection during their lifetime [53].
Moreover, males are more likely to have HPV in their lifetime and be
the recipients of HPV in heterosexual transmission studies [54]. These
data underscore that HPV is not a gender-specific infection.
Feminization of HPV reinforces the long-held belief that women are
responsible for reproductive healthcare in heterosexual partnerships
[8,55]. Traditionally, secondary prevention efforts for HPV and cervical
cancer are solely the responsibility of women as HPV screening is not
available for men [56], further reinforcing this belief. Concomitantly, it
assigns the stigma and blame toward women as both the host and
transmitting agent of HPV [57]. Thus, females are burdened with
screening and treatment of HPV-related diseases, while males both fail
to obtain the primary prevention they need, and accurately perceive
their risk for infection and disease.
Heuristic beliefs that the HPV vaccine is associated with early
sexual behavior among adolescents persist, yet scientific evidence
repeatedly demonstrates that this is not the case [58–60]. Social and
cultural discomfort with female adolescent sexuality is not new. It
stems from a prolonged uneasiness with female sexuality and long held
sexual double standards for males and females. Similar reproductive
health topics, such as adolescent pregnancy, are intractably tied to
young females, who are seen as threatening to society, as well as in
need of protection [61]. The effects of these sexist undertones may be
hindering widespread vaccination efforts. For example, Taylor et al.
[62] suggest parents may delay vaccination past the target range of 11-
to-12 years for females until later in adolescence since sexuality is not a
key concern at this time period.
In addition to the scientific research trajectory, the initial marketing
of the HPV vaccine to females in the U.S. further feminized HPV in the
public mind. As noted above, the 4vHPV vaccine, marketed by Merck
Pharmaceuticals, was approved by in 2006, a full 3 years before Glaxo
Smith-Kline's 2vHPV vaccine, Cervarix, was approved. The GSK
version of the vaccine has never had a strong presence in the U.S. In
expectation of the 2006 licensure of the 4vHPV vaccine, Merck & Co.,
Inc. released two unbranded awareness campaigns in June of that year,
Tell Someone and Make the Connection, targeted at adult women.
These campaigns show women, including a mother and daughter dyad,
expressing their shock at the connection between HPV infection and
cervical cancer and their determination to ‘tell’ everyone in their lives
they care about, including their sister and mother [63]. After the
licensure of Gardasil in October of 2006, Merck released their “One
Less” national print, television, and online advertising campaign
targeting mothers and young women on November 13, 2006. The
preliminary 4vHPV marketing (“One Less” campaign [64]) under-
standably framed the vaccine from the cervical cancer prevention
standpoint and voiced female empowerment as a reason for vaccination
[65]. The declaration of vaccinated girls being “one less” exemplifies
this rhetoric. An unfortunate and unintended consequence of this
campaign was a skewed view that HPV impacted only females [66].
Additionally, this initial marketing campaign failed to directly address
the sexual transmission of HPV and the implications for the prevention
of genital warts [67,68]. Given that the goal of the marketing campaign
was to increase vaccine uptake, it is likely that Merck attempted to
avoid these discussions among the American public who often stigma-
tize, politicize, and misrepresent sexual health issues [68,69]. In 2008,
Merck launched their “I Chose” campaign aimed at catch-up vaccina-
tion aged women. This campaign continues the themes seen in the
“One Less” campaign, with women being empowered to protect
themselves from “two types of HPV that cause cervical cancer, and
the two types that cause other HPV diseases.” However, the ‘other HPV
diseases’ are never identified. Although changes in HPV vaccine
guidelines led to an expansion of marketing for the vaccine that
included males, undertones of HPV as a “woman's disease” continued
to permeate popular media. Moreover, newly developed gender-
neutral, direct-to-consumer advertisements for the vaccine were gen-
erally restricted to women's magazines that targeted mothers with
adolescents [66].
7. The feminization of HPV: consequences for males
The feminization of HPV has had numerous consequences, dis-
advantaging males from receiving a beneficial vaccine and continuing a
sexist rhetoric of HPV primarily impacting females. From a public
health standpoint, if vaccine uptake rates in females were adequate, a
treatise on the feminization of HPV would be essentially unnecessary
because of achieving herd immunity. Unfortunately, we are nowhere
near that threshold. Data on 2014 4vHPV uptake showed that 60% of
females and 42% of males 13-to-17 years had received at least one dose
and 40% of females and 22% of males completed the vaccine series
[70]. Similar trends are observed more distinctly among the catch-up
vaccine groups; among women 18-to-26 years in 2012 the uptake rate
was 34% [71], while among males the uptake rate in 2011–2012 was
only 5.5% [72]. The inequity in the uptake rates among age groups and
genders is indication of the complicated and inconsistent HPV guide-
lines and corresponding timelines. It further illustrates the misunder-
standing that vaccination against HPV is equally important for both
males and females. Indeed, reports on HPV vaccination in the U.S.
typically have focused on low HPV rates among females, not males
[35,73]. This has unfortunately contributed to the misalignment of the
vaccine with females only.
Because the initial approach in the United States focused on
achieving high vaccination rates among females, cost-effectiveness
models have been inadvertently skewed, basing the value of vaccination
only upon one gender. This has mistakenly framed the question as, “is
it cost-effective to vaccinate both males and females compared to
females only” rather than asking “is it cost-effective to vaccinate both
genders compared to not vaccinating anyone?” Additionally, cost-
benefit models tend to underestimate the benefit of male vaccination,
as they include assumptions regarding high female vaccine coverage
[74]. Assessing the cost-effectiveness of the HPV vaccine through
gender-based herd immunity is unlike any other immunization policy
[75].
There is an additional inherent limitation to the herd immunity
thesis as it is based on heteronormative worldviews. The initial logic of
the HPV vaccine and herd immunity ignores MSM, and therefore does
not achieve sufficient protection for all males, especially among a sub-
group at greater risk for HPV-related outcomes. Clinical trial data
among MSM who have been vaccinated with 4vHPV demonstrate a
reduced risk of anal cancer [76], an important outcome for this
population that has higher rates of this cancer [77]. The combination
of a complicated cost-effectiveness approach and heteronormativity has
resulted in stratified and confusing HPV vaccine guidelines for males,
based on sexuality. This can consequently make it more difficult to
MSM to receive the HPV vaccine during “catch-up” years. Some males
may have reservations about disclosing sexual orientation or same-sex
sexual behavior to a healthcare provider; similarly, some healthcare
providers may not be aware of, or ask about, a patient's sexual
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behavior, resulting in missed opportunities for HPV vaccination
[78,79].
The connection of HPV to cervical cancers has overshadowed the
importance of preventing other HPV-related cancers, including oro-
pharyngeal cancers, which affect both males and females.
Oropharyngeal cancer is the second most common HPV-related cancer
in the U.S., and it is projected that by 2020, HPV-related oropharyngeal
cancers will exceed HPV-related cervical cancers [80]. In 2009, new
cases of oropharyngeal cancers accounted for 37.3% of all HPV-
associated cancers, whereas cervical cancers represented 32.7% [81].
It is estimated that 9vHPV could potentially prevent between 6000 and
8000 oropharyngeal cancer cases a year among males – nearly three
times the number of cases among females [82,83]. Yet, there are no
straightforward pre-clinical endpoints for oropharyngeal cancers, nor
are there any approved screening techniques similar to cervical cancer
[84], making it difficult to conduct rigorous shorter-term studies
demonstrating that HPV vaccination prevents pre-oropharyngeal can-
cers. This problem has limited the indications for the HPV vaccine to
the prevention of anogenital diseases. Assuming HPV vaccination does
prevent oropharyngeal cancers, then an unfortunate consequence of
the vaccine being over-identified with females is insufficient protection
for males from these serious cancers.
As a result of the delay in male HPV vaccine approval, studies have
indicated that females have a greater awareness and knowledge of the
HPV vaccine compared to males [85,86]. This is most likely attribu-
table to media and health messages that have targeted females for a
longer period of time. Females and parents of females receive far more
consistent and strong healthcare provider HPV vaccine recommenda-
tions compared to males [87–89], an issue of particular concern in the
U.S. because of the importance of provider recommendation for
vaccine dissemination as opposed to school-based programs [90–92].
Finally, males in the older age of the vaccine catch-up category (22-to-
26 years) may face additional obstacles to receiving the vaccine, not
only due to heteronormative policies, but due in part to “aging out” of
pediatric practices, since males typically do not follow guidelines for
annual exams similar to female gynecological exams [93].
8. Reversing the feminization of the HPV vaccine
The feminization of HPV involves a complicated story intersected
by science, politics, economics and gender norms. Historical events
leading up to the HPV vaccine were driven by both scientific and
economic priorities, necessitating the initial licensure for females.
Given these priorities, and the reliance upon scientific evidence to
drive policy, retrospective decisions to approve the vaccine for both
males and females from 9-to-26 years would have been untenable.
Nonetheless, the failure to create consistent guidance between males
and females at the earliest opportunity underscores the risk of
fragmenting science and policy.
It is encouraging that science and public health policy have begun
to bridge the gap between scholarly evidence and societal norms to
recognize that HPV vaccination is important for all young people. This
is demonstrated by Healthy People 2020 objectives that call for
increase in HPV vaccine 3-dose coverage among 13-to-15 year old
females and males to 80% [94]. Unfortunately, rates of vaccination in
the U.S. are dismal compared to the public health targets. Thus,
implementation of these national objectives will be challenging. We
believe that a national movement is required to implement state-by-
state legislation and policy for school-based entry for HPV vaccination
that is gender neutral. This will require coordination from multiple
stakeholders: healthcare providers, parents, young adults, state-level
policymakers, public health agencies, and professional organizations.
Normalization of HPV vaccination is needed for this prevention
strategy, despite associated controversy. Moreover, if we fail to face
the issue of feminization of HPV directly, we will continue to
perpetuate these consequences.
Thus, in order to improve HPV vaccination, we suggest a multilevel
approach in normalizing HPV vaccines as an important aspect of
overall health for all individuals. This approach includes policy
strategies, provider education and communication tools, targeted
patient messages, and coordinated action among providers and scho-
lars. Borrowing from the social ecological model of health, we assert
that a gender-neutral strategy for HPV vaccination must involve key
agents at every level of influence to normalize HPV as gender-neutral
[95]. Additionally, this strategy must consider the longstanding gender
beliefs that contribute to the feminization of HPV. Disentangling
adolescent female sexuality and protection of women only from these
messages are required for a gender-neutral approach.
At a policy level, we advocate normalizing HPV vaccination through
school entry requirements with strict exemption guidelines, identical to
those for other adolescent vaccines. In making the HPV vaccine a
requirement for school entry, the vaccine can instead be viewed as one
of the vaccines necessary for school-age children. While requiring HPV
vaccination for school entry would potentially normalize the vaccine
and increase uptake, initial resistance to normalizing HPV vaccination
through schools may persist. Additionally, we must consider the
implementation of previous HPV vaccine mandates that have been
less than successful, and learn from these efforts. For example, Virginia
enacted a school-entry mandate in 2008 for HPV vaccination among
girls, but this mandate had a philosophical exemption that has largely
contributed to the lack of improvement in vaccination rates [96]. In
contrast, Rhode Island's HPV vaccine mandate does not include this
language, and may prove to be more successful, as it does not include
lenient exemption policies [96]. We argue for strict exemption guide-
lines that are limited to religious or medical exemptions only.
In addition to normalizing HPV vaccination through policy, nor-
malization must occur through primary care physicians (e.g., pediatri-
cians, family practice, and OB/GYNs). Existing evidence suggests these
physicians may be hesitant to recommend HPV vaccines [97], but
providers play an important role in determining whether patients
complete a vaccine series. Accordingly, we suggest strong statements
from providers’ professional organizations and accompanying commu-
nication tools that give providers an effective and persuasive means
through which to recommend HPV vaccination to parents. Moreover,
professional organizations must encourage all clinical staff to discuss
and promote the HPV vaccine since staff members can play supportive
roles in reinforcing positive health messages. Provider-focused messa-
ging is especially important in the current time period given the advent
of 9vHPV, which allows for providers to contextualize new HPV
messages as a form of emerging evidence to reframe existing narratives
about HPV. The introduction of 9vHPV and eventual discontinued use
of 4vHPV provides an ideal time for providers to discuss this topic with
parents and explain the latest vaccine as a way to protect all people
from HPV-related disease.
Similarly, the emergence of 9vHPV provides an opportunity for
public health agencies such as the CDC to implement messages
targeting both unvaccinated individuals and parents with vaccine-
eligible children. Rather than reproducing the gendered messages of
4vHPV, 9vHPV messages must include gender-neutral information
that challenges existing views of HPV. Such messages can normalize
HPV vaccination by emphasizing its importance for males and females
in the same regard as other vaccines. These messages can simulta-
neously defeminize HPV and emphasize the importance of all vaccines
for protecting against preventable causes of death and disease.
Agencies should design these messages in consultation with academic
researchers, providers, and community organization groups to ensure
their relevance in advancing gender-neutral HPV ideals.
9. Conclusion
HPV has a long history of feminization that has been perpetuated
by the intersection of science, politics, economics and gender norms.
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Not only has the feminization of HPV supported historic rhetoric of
gender inequality, which adversely impacts females, but has also
directly impacted males by resulting in lower-than-expected HPV
vaccination rates. In our suggestions for normalizing HPV vaccination
and making it gender neutral, we assert a need for multilevel
approaches targeting providers, patients, parents, professional organi-
zations, public health agencies, policymakers, researchers, and com-
munity-based organizations. This approach can combat the conse-
quences of feminization and potentially increase the likelihood of
changing existing assumptions about HPV.
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